[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555436":3},{"organization":4,"armGroups":7,"interventions":30,"overallOfficials":37,"centralContacts":41,"locations":51,"responsibleParty":80,"collaborators":83,"id":88,"slug":89,"hasResults":90,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":33,"eligibilityCriteria":94,"healthyVolunteers":95,"sex":96,"minAge":97,"maxAge":98,"enrollmentInfo":99,"targetDuration":36,"studyType":102,"phases":103,"briefSummary":105,"conditions":106,"keywords":36,"overallStatus":53,"whyStopped":36,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"Indiana University","OTHER",[8,14,18,22,26],{"label":9,"type":10,"description":11,"interventionNames":12},"Asthma","EXPERIMENTAL","Physician diagnosis plus at least one of the following in the past year: asthma symptoms that improve with albuterol; prescribed asthma controller medication(s); an acute asthma exacerbation requiring systemic steroids; or an emergency department visit or hospitalization for asthma. Alternatively, report of current asthma symptoms per US NAEPP or Global Initiative for Asthma (GINA) guidelines, plus documentation of bronchodilator response or airway hyperresponsiveness.",[13],"Diagnostic Test: AWARE",{"label":15,"type":10,"description":16,"interventionNames":17},"Chronic Obstructive Pulmonary Disease (COPD)","Physician diagnosis, plus symptoms of COPD per GOLD guidelines, plus post-bronchodilator FEV1\u002FFVC \\\u003C0.70 or below the lower limit of normal (LLN) using GLI reference equations.",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Cystic Fibrosis (CF)","Physician diagnosis based on U.S. CF Foundation guidelines, including signs\u002Fsymptoms of CF and either a positive sweat chloride test (\\>60 mmol\u002FL), or an indeterminate sweat chloride test (30-59 mmol\u002FL) plus two CF-causing CFTR mutations. The study may include subjects with different CFTR mutation classes as well as both on and off CFTR modulators.",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"Other Airway Diseases","This group will include subjects with airway ciliary motility disorders, bronchiectasis, and airway malaria. Given variability in the clinical presentation and diagnosis of these conditions, they will be ascertained by physician diagnosis and reviewed by study physician investigators.",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"Healthy Controls","This will include generally healthy subjects who do not have any of the airway diseases included in the study, nor other chronic cardiorespiratory or other diseases that may alter lung function or the ability to participate in the study.",[13],[31],{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"DIAGNOSTIC_TEST","AWARE","AWARE testing to estimate lung function and aid in disease diagnosis",[9,15,19,27,23],null,[38],{"name":39,"affiliation":5,"role":40},"Erick Forno, MD MPH","PRINCIPAL_INVESTIGATOR",[42,47],{"name":43,"role":44,"phone":45,"phoneExt":36,"email":46},"Elizabeth Rizzi, RN","CONTACT","317-626-6937","lizbuell@iu.edu",{"name":48,"role":44,"phone":49,"phoneExt":36,"email":50},"Lisa Bendy, RRT","317-278-7152","lbendy@iu.edu",[52,67],{"facility":5,"status":53,"city":54,"state":55,"zip":56,"country":57,"countryCode":58,"cosmosGeoPoint":59,"geoPoint":64,"contacts":65},"RECRUITING","Indianapolis","Indiana","46202","United States","US",{"type":60,"coordinates":61},"Point",[62,63],-86.15804,39.76838,{"lat":63,"lon":62},[66],{"name":39,"role":44,"phone":36,"phoneExt":36,"email":36},{"facility":68,"status":53,"city":69,"state":70,"zip":71,"country":57,"countryCode":58,"cosmosGeoPoint":72,"geoPoint":76,"contacts":77},"University of Pittsburgh","Pittsburgh","Pennsylvania","15224",{"type":60,"coordinates":73},[74,75],-79.99589,40.44062,{"lat":75,"lon":74},[78],{"name":79,"role":44,"phone":36,"phoneExt":36,"email":36},"Juan C Celedón, MD DrPH",{"type":40,"investigatorFullName":81,"investigatorTitle":82,"investigatorAffiliation":5,"oldNameTitle":36,"oldOrganization":36},"Erick Forno","Professor of Pediatrics",[84,87],{"name":85,"class":86},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",{"name":68,"class":6},"100555436","acoustic-waveform-respiratory-evaluation-100555436",false,"NCT06512064","Acoustic Waveform Respiratory Evaluation","Advancing Telemedicine in Pulmonology: Acoustic-waveform Respiratory Evaluation (AWARE) Via Sensing and Machine Learning on Smartphones","Inclusion Criteria:\n\n1. Age 8-70 years\n2. Ability to perform spirometry and oscillometry\n3. Signed informed consent (and assent for children as appropriate)\n4. No respiratory or other major disease (for healthy controls), or physician-diagnosed asthma, COPD, CF, or other airway diseases\n\nExclusion Criteria:\n\n1. Inability or unwillingness to perform AWARE, spirometry, or oscillometry\n2. Acute or chronic illness that, at the judgement of investigators, may affect lung function and alter the results of AWARE or the reference PFTs (spirometry and AOS)",true,"ALL","8 Years","70 Years",{"count":100,"type":101},800,"ESTIMATED","INTERVENTIONAL",[104],"NA","The study will evaluate the feasibility of using smartphone speakers and microphones to evaluate the caliber of the airways, detect airway obstruction, aid in airway disease diagnosis, and identify disease exacerbations.",[9,107,108,109,110,111,112],"COPD","Cystic Fibrosis","Ciliary Motility Disorders","Bronchiectasis","Airway Malacia","Healthy Control","2025-10-23",{"date":115,"type":116},"2025-10-24","ACTUAL",{"date":118,"type":116},"2024-07-23",{"date":120,"type":101},"2029-04",{"name":5,"class":6},2]